News|Articles|November 20, 2026

PARADIGM and the Fit Patient: Rethinking Induction Intensity in AML

Listen
0:00 / 0:00

Key Takeaways

  • Randomization against 7+3/CPX-351 provided rare prospective evidence that AZA-VEN can outperform intensive induction in fit AML patients by EFS and overall response rates.
  • Clinically relevant advantages included higher allo-HCT rates (~60% vs ~40%), fewer grade ≥3 infections (28% vs 41%), less severe hemorrhage (2% vs 12%), and reduced hospitalization/early mortality.
SHOW MORE

A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.

For decades, the choice between intensive and lower-intensity induction in acute myeloid leukemia (AML) has largely come down to a patient’s age, performance status, and ability to tolerate chemotherapy. The phase 2 PARADIGM trial (NCT04801797) challenges that framework. It randomly assigned 172 medically fit patients with newly diagnosed AML to azacitidine (Vidaza; Bristol Myers Squibb) plus venetoclax (AZA-VEN) or intensive chemotherapy with 7+3 or CPX-351. AZA-VEN significantly improved event-free survival, produced higher response rates, and allowed more patients to proceed to allogeneic hematopoietic cell transplantation, with fewer severe infections and bleeding events.

In this interview, Sanja Zepcan, PharmD, BCPS, BCOP, clinical pharmacy specialist of hematology/oncology, bone marrow transplant, and cellular therapy at Loyola University Medical Center, discusses the trial’s findings, which she presented as part of the panel discussion “AML Treatment: Lower Intensity—But Deceptively Strong” at the Blood Cancer United Acute Leukemia & Myeloid Malignancies Rounds.

She also explains where the data fall short, including the lack of a significant overall survival benefit and imbalances in baseline molecular characteristics between the arms, and what broader use of AZA-VEN would mean for oncology pharmacists managing drug interactions, myelosuppression, and the bridge to transplant.

For pharmacists who may not be familiar with it, what question was the PARADIGM trial designed to answer, and why does it challenge the traditional way we choose between intensive and lower-intensity induction in AML?

For more than five decades, intensive induction chemotherapy, traditionally cytarabine plus an anthracycline (7+3), has been the backbone of treatment for medically fit patients with newly diagnosed AML. The decision between intensive and lower-intensity therapy has largely been based on age, performance status, comorbidities, and the patient's ability to tolerate intensive chemotherapy.

The introduction of azacitidine plus venetoclax (AZA-VEN) changed the treatment landscape for older or medically unfit patients. Following the VIALE-A trial, AZA-VEN became an established standard of care for patients ineligible for intensive induction. However, we had limited prospective randomized evidence comparing this approach directly with intensive chemotherapy in patients considered fit enough to receive either regimen.

The PARADIGM trial was designed to address this question: Can a lower-intensity regimen provide superior outcomes to intensive induction chemotherapy in patients who are medically fit for intensive treatment?

This investigator-initiated, randomized phase II trial enrolled 172 patients with newly diagnosed AML who were eligible for intensive induction and compared AZA-VEN with 7+3 or CPX-351. The primary endpoint was event-free survival (EFS).

What makes PARADIGM particularly important is that it challenges our traditional treatment-selection framework. Rather than assuming that medically fit patients should receive intensive chemotherapy, it encourages us to consider whether disease biology, treatment efficacy, toxicity, and the patient's long-term treatment strategy should play a greater role in selecting induction therapy.

What were the most important findings from PARADIGM, and how did your session at the Blood Cancer United Acute Leukemia & Myeloid Malignancies Rounds frame them as “Lower Intensity—But Deceptively Strong”?

PARADIGM demonstrated a significant improvement in event-free survival (EFS) with azacitidine plus venetoclax (AZA-VEN) compared with intensive chemotherapy. At a median follow-up of 21.9 months, median EFS was 14.5 versus 6.2 months, respectively (HR, 0.57; 95% CI, 0.39–0.84; P = .002), representing a 43% relative reduction in the hazard of an event or death. Overall response rates were also higher with AZA-VEN (88% versus 62%), as were composite complete remission rates, including CR, CR with partial hematologic recovery, and CR with incomplete hematologic recovery (78% versus 53%). However, conventional CR rates were more similar between groups (56% versus 49%).

One of the most clinically meaningful findings was the higher proportion of patients proceeding to allogeneic hematopoietic cell transplantation (allo-HCT): approximately 60% with AZA-VEN compared with 40% with intensive chemotherapy.

The safety findings were equally compelling. Grade 3 or higher infections occurred in 28% versus 41% of patients, and severe hemorrhagic events occurred in 2% versus 12%, favoring AZA-VEN. The lower-intensity group also experienced fewer hospital days and lower early mortality.

However, these findings must be interpreted in the context of the study population and eligibility criteria. Although PARADIGM enrolled adults aged 18 years or older who were considered eligible for intensive induction chemotherapy, the median ages were approximately 64 and 65 years in the two treatment arms. Therefore, despite enrolling medically fit patients, the study population was predominantly older rather than representative of the entire spectrum of younger, fit patients with newly diagnosed AML.

Importantly, the trial excluded several molecular subgroups for which established treatment approaches differ, including patients with core-binding-factor AML, patients with FLT3 mutations meeting the protocol exclusion threshold, and patients younger than 60 years with NPM1-mutated AML. These exclusions are clinically relevant because patients with FLT3-mutated AML have established intensive chemotherapy approaches incorporating FLT3 inhibitors, while patients with core-binding-factor AML commonly receive intensive chemotherapy with consideration of gemtuzumab ozogamicin. NPM1-mutated AML is also more frequently encountered in younger patients compared with certain adverse-risk molecular subtypes, although its prevalence and treatment implications vary by age and co-occurring mutations.

Additionally, the older age distribution is important when considering disease biology. Mutations involving IDH1, IDH2, and TP53, as well as AML with myelodysplasia-related features or secondary AML, are clinically relevant in older populations. These disease characteristics may influence both the response to venetoclax-based therapy and the outcomes associated with conventional intensive induction.

Taken together, PARADIGM's findings are most directly applicable to a selected, predominantly older population of medically fit patients with intermediate- or adverse-risk AML, rather than all patients eligible for intensive chemotherapy. The results suggest that AZA-VEN may offer meaningful efficacy and tolerability advantages in this population, particularly when the goal is to achieve remission and proceed to allo-HCT. However, they should not be generalized to younger patients with favorable-risk disease or molecular subgroups excluded from the trial, for whom established intensive and targeted induction strategies remain important.

During our Blood Cancer United panel discussion, “AML Treatment: Lower Intensity—But Deceptively Strong,” we explored both sides of the debate: whether lower-intensity therapy may offer superior efficacy and tolerability, and why intensive chemotherapy continues to have an important role in selected patients.

From my perspective as a transplant pharmacist, the higher proportion of patients reaching allo-HCT was particularly interesting. For many patients with intermediate- or adverse-risk AML, transplantation represents the best opportunity for long-term disease control. A regimen that achieves remission while minimizing treatment-related complications may allow more patients to reach transplantation in an appropriate clinical condition.

However, more patients reaching transplantation does not necessarily mean more patients are cured. The trial did not demonstrate a statistically significant overall survival benefit, and longer follow-up is needed to understand whether the improvement in EFS and transplant access translates into improved long-term outcomes.

That distinction was central to the discussion: lower-intensity treatment may be deceptively strong, but we must carefully distinguish promising efficacy findings from definitive evidence of improved survival.

Historically, fitness and age have driven the intensive versus lower-intensity decision. Based on PARADIGM, which patients should we now be reconsidering, and are there groups for whom intensive chemotherapy still clearly remains the preferred approach?

The most important shift is that fitness alone should no longer be the primary determinant of induction intensity. We should increasingly incorporate molecular characteristics, measurable residual disease considerations, transplant eligibility, treatment-related toxicity, and patient preferences into treatment selection.

PARADIGM provides greater confidence in choosing AZA-VEN for selected medically fit patients who could reasonably receive either intensive or lower-intensity induction, particularly when the ultimate goal is to achieve remission and proceed to allo-HCT. In these patients, the ability to achieve disease control while minimizing treatment-related complications and preserving performance status may be just as important as the intensity of induction itself.

From a transplant perspective, the higher proportion of patients proceeding to allo-HCT with AZA-VEN is particularly encouraging. Although longer follow-up is needed to determine whether this translates into improved post-transplant outcomes and overall survival, the findings support considering lower-intensity induction as a viable bridge to transplantation rather than reserving it exclusively for patients who are unfit for intensive chemotherapy.

At this point, I would consider AZA-VEN a compelling alternative for selected induction-eligible patients rather than a universal replacement for intensive chemotherapy.

If lower-intensity regimens are used more often in fit patients, what changes for the oncology pharmacist in terms of dosing, drug interactions, supportive care, and monitoring for toxicities such as myelosuppression?

Although AZA-VEN is considered a lower-intensity regimen, it is not necessarily a lower-complexity regimen. In many ways, its broader use would increase the importance of oncology pharmacist involvement in treatment optimization and supportive care.

One of the most significant considerations is the management of drug–drug interactions. Venetoclax is metabolized primarily through CYP3A, and strong CYP3A inhibitors, particularly azole antifungals such as posaconazole and voriconazole, can substantially increase venetoclax exposure.

These interactions require appropriate venetoclax dose reductions and careful review of the patient's complete medication profile. For example, when posaconazole is administered concurrently, venetoclax generally requires a substantial dose reduction, with the exact dose depending on the treatment phase and prescribing guidance.

Myelosuppression is another major consideration. Although AZA-VEN was associated with fewer severe infections than intensive chemotherapy in PARADIGM, prolonged neutropenia and thrombocytopenia remain common and can lead to infections, transfusion requirements, and treatment delays.

Pharmacists play an important role in coordinating bone marrow assessments, interpreting whether cytopenias are related to persistent leukemia or treatment, and recommending appropriate venetoclax duration adjustments and cycle delays once remission is achieved.

Other important responsibilities include tumor lysis syndrome risk assessment and prophylaxis, antimicrobial prophylaxis, renal and hepatic function monitoring, and coordination of outpatient supportive care.

From a transplant perspective, we also need to consider how induction therapy affects the patient's overall treatment trajectory. Maintaining disease control while minimizing infections, organ toxicity, and functional decline may be critical for patients preparing for allo-HCT.

Ultimately, the goal is not simply to administer a less-intensive regimen, but to deliver it safely and effectively while preserving the patient's opportunity for long-term disease control.

What questions does PARADIGM leave unanswered, and what would you want to see from future studies or real-world data before this approach becomes standard practice?

PARADIGM is an important study that challenges our traditional approach to AML induction, but several questions remain unanswered.

First, although event-free survival (EFS) was significantly improved, the study did not demonstrate a statistically significant overall survival advantage. We need longer follow-up to determine whether the observed benefits translate into improved long-term survival and potentially cure.

Second, the primary endpoint deserves careful interpretation. EFS included persistent disease prompting a treatment change, which was determined by the treating investigator in an open-label study. Because response assessment and treatment decisions may differ between AZA-VEN and intensive chemotherapy, this could influence the timing of EFS events.

Third, we need more information regarding molecular subgroups. AML is a biologically heterogeneous disease, and the effectiveness of AZA-VEN compared with intensive chemotherapy may vary considerably depending on molecular characteristics. Importantly, the treatment arms were not completely balanced in terms of baseline molecular characteristics. Patients with IDH1/IDH2 and NPM1 mutations were more frequently represented in the AZA-VEN arm, whereas TP53 mutations were more common in the intensive chemotherapy arm. This imbalance is clinically relevant because NPM1- and IDH-mutated AML are generally associated with greater sensitivity to venetoclax-based therapy, whereas TP53-mutated AML is associated with poor outcomes regardless of treatment intensity. These differences may have contributed to the observed efficacy advantage with AZA-VEN, although the extent of their influence cannot be determined from this relatively small phase II trial. Larger prospective studies with appropriate molecular stratification would help identify which patients benefit most from each approach.

Another interesting aspect of PARADIGM is the heterogeneity of the intensive chemotherapy comparator arm, which included both conventional 7+3 (54%) and CPX-351 (Vyxeos; 46%). CPX-351 is commonly used for therapy-related AML and AML with myelodysplasia-related features, making this finding particularly relevant to patients with secondary AML. The results provide an encouraging signal that AZA-VEN may be a reasonable alternative to CPX-351 for selected medically fit patients with secondary or myelodysplasia-related AML, particularly when the goal is to achieve remission and proceed to transplantation. However, combining two distinct intensive induction regimens within a single comparator arm makes it difficult to determine whether the observed benefit with AZA-VEN was consistent across both treatment strategies. PARADIGM was not designed or powered to establish superiority of AZA-VEN over CPX-351 or 7+3 individually, and additional prospective studies are needed before drawing definitive conclusions about the optimal induction approach for these patient populations.

Fourth, I would like to see more detailed transplant-specific outcomes. Although a higher proportion of patients receiving AZA-VEN proceeded to allogeneic hematopoietic cell transplantation (allo-HCT), we need to understand whether this translates into differences in pretransplant measurable residual disease (MRD) status, post-transplant relapse, nonrelapsemortality, and long-term survival.

Another important implication of PARADIGM is that it strengthens the rationale for using AZA-VEN as a backbone for the next generation of molecularly targeted combination therapies. Ongoing clinical trials are investigating triplet regimens incorporating AZA-VEN with targeted agents, including menin inhibitors for NPM1-mutated and KMT2A-rearranged AML and FLT3 inhibitors for FLT3-mutated disease. These approaches may further improve remission depth, MRD negativity, and durability of response while potentially avoiding some of the toxicities associated with intensive chemotherapy. However, whether these triplet combinations improve survival or can replace contemporary targeted intensive induction remains to be demonstrated in randomized studies.

Finally, real-world studies will be essential. PARADIGM was conducted at experienced academic centers, and we need to determine whether similar efficacy, safety, and healthcare utilization outcomes can be reproduced in broader clinical settings. Future studies should also evaluate patient-reported outcomes, quality of life, treatment burden, and the long-term impact of repeated AZA-VEN cycles compared with intensive induction followed by consolidation or transplantation.

Overall, I believe PARADIGM represents an important step toward moving beyond the traditional distinction between intensive and lower-intensity induction in AML. The findings provide greater confidence in selecting AZA-VEN for certain medically fit patients who are candidates for either approach, particularly older patients with intermediate- or adverse-risk disease for whom the goal is to achieve remission and proceed to allogeneic transplantation. However, the molecular imbalances between treatment arms, heterogeneity of the intensive chemotherapy comparator, and lack of a demonstrated overall survival advantage highlight the need for further investigation before broadly changing the standard of care.

PARADIGM also reinforces the potential of AZA-VEN as a backbone for emerging molecularly targeted triplet regimens, including combinations with menin and FLT3 inhibitors, which may further transform frontline AML treatment.

Rather than replacing intensive chemotherapy, PARADIGM encourages a more individualized, biology-driven approach to induction therapy. The question is no longer simply whether a patient is fit enough to receive intensive chemotherapy, but whether intensive chemotherapy is the most appropriate treatment for that patient's AML, particularly when the ultimate goal is to achieve remission and successfully bridge the patient to transplantation.


Related to this article